Premium
P3‐020: Differential diagnosis of neurodegenerative diseases using serum: A new paradigm
Author(s) -
Goldknopf Ira L.,
Marcopoulou Katerina,
Chase Bruce A.,
Appel Stanley H.,
Sabbagh Marwan
Publication year - 2009
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2009.04.1197
Subject(s) - amyotrophic lateral sclerosis , medicine , biomarker , parkinsonism , atrophy , disease , pathology , parkinson's disease , differential diagnosis , stroke (engine) , gastroenterology , oncology , biology , mechanical engineering , biochemistry , engineering
Background: With research in preventative medicine and early treatment gaining fast momentum, the importance of detection, in particular early detection of Alzheimer’s disease (AD) is now prevalent. On top of the growing list of known biomarkers of AD is Amyloid-b (Ab) which has long being known as central to the pathology of AD. Although the detection of its two major isoforms in cerebrospinal fluid (CSF) has been well established, a high degree of invasiveness involved in sample collection of CSF prevents its usefulness for detection in the wider community. Recent studies have turned to blood products as an attractive alternative but had resulted in conflicting results. One of the contributing factors to conflicting results may be the low amount of participant in these studies. We present here the biomarker studies from the first phase of The Australian Imaging, Biomarker and Lifestyle (AIBL) Flagship Study of Ageing. Methods: Blood plasma samples of over 1000 participants across two cities in Australia were collected and analysed for the levels of the two isoforms Ab-40 and Ab-42 using the INNO-BIA Ab detection kits. Neuropsychological assessment data of the participants were correlated against the levels of Ab40 and Ab42. Results: Mild cognitively impaired patients (MCI) showed significantly higher levels of Ab-42 that subsequently caused the increase of Ab-42/Ab-40 ratio when compared with healthy volunteers (HV) and memory complaining volunteers (MC). Conclusions: Even with the statistical power of over 1000 participant samples collected, it was still uncleared as to whether blood plasma Ab levels can determine differences between AD patients and HV. We showed evidence that the levels of other plasma biomarkers may also help when taken into account with plasma Ab levels. However, with the second phase of AIBL study on the way which will incorporate data collected at 18 months from the phase I studies, a clearer relationship between Ab and AD will be promising.